1 Deep Venous Thrombosis and Pulmonary Thromboembolic Disease: Are we practicing evidence-based medicine? The 2012 ACCP Guidelines and Beyond (Buzz Lightyear) Jeffrey L. Garland, MD, FCCP Associate Chair for Hospital Practice, Department of Medicine Consultant, Departments of Pulmonary and Critical Care Medicine Mayo Clinic Florida Jacksonville, Fl
2 Antithrombotic Therapy and Prevention of Thrombosis, 9 th Edition : ACCP Evidence-Based Clinical Practice Guidelines CHEST February 2012, vol 141 Supplement
3 Grading Recommendation Strength Grade 1: Strong Recommendation. Benefits do (or do not) outweigh risks and burdens. Worded as ACCP Recommends Grade 2: Weak Recommendation. Benefits and risks are closely balanced or are uncertain. Worded as ACCP Suggests
4 Grading the Quality of the Evidence Grade A: High Quality. One or more well designed and executed randomized controlled trials with consistent results, or multiple observational studies with large consistent effects. Grade B: Intermediate Quality. Grade C: Low Quality. Small observational studies or randomized controlled trials with multiple limitations.
5 Which one of the following is not a first line recommendation for the initial treatment of an acute DVT or PE? 1. SQ Low Molecular Weight Heparin 2. SQ Fondaparinux 3. SQ Unfractionated Heparin 4. IV Unfractionated Heparin 5. All of the Above are acceptable as first line treatment of an acute DVT.
6 Answer: All of the above. LMWH, IV or SQ weight-adjusted UFH, Fondaparinux (ACCP 1B recommendations) (and most recently, Rivaroxaban), are approved for the treatment of acute DVT and PE. Enoxaparin (lovenox) 1.5 mg/kgm once daily is weakly preferred over a dose of 1 mg/kgm twice daily (2C). All five options should be used for a minimum of 5 days and INR >=2.0 for at least 24 hrs (1B).
7 Recommendations among the Four Approved Agents in the treatment of acute DVT or PE Hemodynamically Stable: Use LMWH over IV UFH (1B) and over fondaparinux (2C). Use fondaparinux over IV UFH (2B). LMWH vs IV UFH studies show lower mortality, fewer recurrent VTE s, and less major bleeding. Use IV UFH (2B) in patients with persistent hypotension, increased risk of bleeding, severe renal failure (CrCl<30), concerns about SQ absorption (such as obesity or anasara), or in whom thrombolysis may be performed.
8 Relative Risk of Major Bleeding Definition of Major Bleeding: ICH, Retroperitoneal Hem, or bleeding that leads to death, hospitalization, or transfusion. LMWH lower risk than IV UFH (1.2% vs 2.0%). LMWH similar to fondaparinux and SQ UFH. Protamine reduces bleeding by neutralizing antithrombin activity in all but fondaparinux.
9 Relative Risk of HIT Risk of HIT lower in LMWH than in IV UFH or SQ UFH. SQ Fondaparinux has only case reports showing an infrequent association with HIT (causality not proven).
10 Long-term Treatment of Acute DVT or PE Warfarin preferred over LMWH except in patients with malignancy. Warfarin or LMWH preferred over Rivaroxaban due to the paucity of experience with Rivaroxaban.
11 Long-term Treatment of an Acute DVT Warfarin should be started on Day 1 (1B). Use 10 mg dose the first 2 days (2C). Initial treatment at home over hospital if home circumstances allow (1B). Early ambulation over bedrest (2C). Asymptomatic DVT should get the same treatment as symptomatic DVT (2B). Compressive stockings for 2 years for symptomatic DVT s to prevent PTS (2B).
12 Major Bleeding on Warfarin Suggest rapid reversal of AC with fourfactor prothrombin complex concentrate (Factors IX,II,X,VII/ Bebulin) rather than with FFP (2C). Also use vitamin K 5-10 mg slow IV injection (2C).
13 For how long should warfarin be continued in the treatment of an acute DVT in a patient with a reversible risk factor? (provoked DVT) 1. 6 weeks 2. 3 Months Months months 5. Indefinite Treatment
14 Answer: 3 Months Warfarin for 3 months has been shown better than warfarin for 6 weeks (1B) in reduction of recurrent VTE and is recommended over longer treatment (1B). Longer treatment is associated with additional bleeding risk w/o reduction in recurrent VTE. For first time unprovoked DVT: Warfarin for a minimum of 3 months (1A). Continue indefinitely if at low or moderate risk of bleeding (2B). If high risk of bleeding use just 3 months (1B).
15 Duration of DVT Treatment Continued For second time unprovoked DVT use indefinite AC in patients at low risk of bleeding (1B) or moderate risk (2B). If high risk of bleeding just 3 months of AC (2B).
16 What long-term treatment should be recommended for patients with DVT in the face of a Malignancy? 1. 3 months of warfarin 2. Indefinite warfarin 3. 3 months of LMWH 4. Indefinite LMWH 5. IVC Filter placement
17 Answer: LMWH indefinetely LMWH is suggested over warfarin with Grade 2B evidence. LMWH is recommended indefinitely in patients at low to moderate bleeding risk (1B) and in patients at high bleeding risk (2B).
18 Catheter-Directed Thrombolysis (CDT) Considered in patients with extensive acute DVT with SX s for < 14 days, good functional status and life expectancy, with low risk of bleeding (2B) Subsequent treatment same as for patients who did not get CDT (1B) Systemic thrombolysis can be used if CDT is not available (2C)
19 Which of the following is an indication for IVC Filter Placement in a patient with an acute DVT? 1. Contraindication to Anticoagulation (AC) 2. Failure of Anticoagulation 3. Massive DVT 4. Massive PE 5. All of the above
20 Answer: Contraindication to AC Contraindication to AC has a Grade 1B recommendation. The other potential indications are commonly employed, but w/o EBM to support them. Often placed for contraindication of AC, failure of AC, and for massive or submassive PE in whom TPA is not being given. Give conventional AC when possible (2B). Do not need AC solely because of the presence of the filter.
21 Treatment of PE In low-risk PE patients with adequate home circumstances suggest home treatment (2B).
22 In the absence of a high risk of bleeding, thrombolysis is suggested for a PE in which of the following circumstances? 1. Massive PE with hypotension 2. Submassive PE with hypoxemia 3. Submassive PE with severe RV strain on echo 4. Submassive PE with elevated Troponin 5. All of the above circumstances
23 Answer: Massive PE with hypotension (SBP < 90) (Grade 2C) In addition, thrombolysis can be considered in selected patients at high-risk for developing hypotension who are at low risk of bleeding (2C) Thrombolysis should be given IV, not catheter directed (2C). It is as effective when given by IV as by CDT, with no increased risk of bleeding, and with a lower risk for mechanical complications. 2 hr infusion time recommended (2C).
24 Treatment of PE with Thrombolytics Metanalysis of 748 patients from 11 randomized controlled trials of AC plus Lytic vs AC alone. Lytic with trend toward reduction in recurrent PE, all-cause mortality, increase in major bleeding. 5 of these trials with more severe PE: significant decrease in mortality (6.2% vs 12.7%) and increase in major bleeding (21.9% vs 11.9%).
25 Treatment of PE with Lytics Positive Effects of Lytics: accelerated clot lysis, decrease in PA pressures, normalization of RV function. High risk patients where can consider Lytics : marked dyspnea and low sats, elevated troponin (indicative of RV microinfarction), RV dysfunction on echo, RV enlargement on Chest CT.
26 Treatment of PE When should IR catheter extraction or fragmentation, or surgical embolectomy be considered in Acute PE? What is the level of evidence for this?
27 Treatment of PE In patients with PE causing hypotension and major contraindication to thrombolytic, or insufficient time to wait for thrombolytic effect, and appropriate expertise is available. 2C.
28 Treatment of PE When should an IVC Filter be placed?
29 Treatment of PE If AC is contraindicated (1B). Conventional course of AC should be resumed when possible (2B).
30 Treatment of PE Duration of Therapy with coumadin or LMWH is the same as for DVT.
31 Upper Extremity DVT What is recommended for the initial treatment of an acute UE DVT? Should CDT be given?
32 Upper Extremity DVT LMWH, IV or SQ UFH, or fondaparinux followed by warfarin for 3 months(1b). Only consider catheter directed thrombolytic in patients with low risk of bleeding and severe symptoms of recent onset (2C).
33 Upper Extremity DVT When should a SVC Filter be considered? How long should coumadin be used? Should the CVP be removed?
34 Upper Extremity DVT Consider filter if AC contraindicated and there is clear evidence of DVT progression or clinically significant PE (2C). Warfarin for 3 months (1B) similar to Reversible cause of a LE DVT. Do not remove CVC if it is still needed (2C). Keep AC going as long as catheter is in place (1C with cancer, 2C without).
35 Heparin-induced Thrombocytopenia HIT-1: Non-immune mediated small fall in platelet count within the first 2 days of starting heparin. Of no clinical significance. Do not need to stop Heparin. HIT-2: Immune Mediated with antibodies against Heparin. 2.6 % incidence with UFH vs ony 0.2% with LMWH.
36 When should a diagnosis of HIT-2 (HIT) be expected? Received Heparin within the past 2 weeks (most typically within 5-10 days after initiation of Heparin therapy) and Platelet count drop >= 50% or Thrombotic event between days 5-14 of heparin initiation (1C)
37 Treatment of HIT Treatment with bivalirubin or argatroban. (Fondaparinux can be considered for off label use). HIT and cardiac surgery: delay surgery if possible. Otherwise use bivalirubin (2C). HIT and needing PCI: use bivalirudin (2B). HD patients with h/o HIT should get citrate rather than heparin (2C).
38 D-Dimer Assay More than a half dozen different assays are available to measure the D-Dimer. For the quantitative assays a D-Dimer level > 500 ng/ml is considered abnormal. Good sensitivity and NPV for DVT/PE. Sensitivity 95% by quantitative rapid ELISA (30 min test). Poor specificity and PPV. Normal in only 40-70% of patients without PE.
40 D-Dimer Testing is Recommended in which of the Following Circumstances? 1. Patient with a moderate pre-test probability of DVT. 2. Patient with a high pre-test probability of DVT. 3. Patient with a high pre-test probability of PE. 4. None of the above. 5. All of the above.
41 Answer: Patient with a moderate pre-test prob for DVT Low or moderate prob of DVT: check D- dimer. If negative no further w/u is needed (1B). If positive get an US. High prob of DVT: check US. If US positive then treat. High prob of DVT: If US negative then check D-dimer. If D-dimer positive repeat US in one week.
43 USE OF NEWER AGENTS: FDA APPROVAL **Rivaroxiban (Oral Factor Xa inhibitor): Acute DVT/PE, Prevent recurrence DVT/PE, Hip/Knee Surgery prophylaxis, Non-valvular Afib. Abixiban (Oral Factor Xa inhibitor): Non-valvular Afib. Edoxaban (Oral Factor Xa inhibitor): None. Dabigatran ( Oral Direct Thrombin Inhibitor): Non-Valvular Afib.
44 USE OF NEWER AGENTS: FDA APPROVAL **Fondaparinux (SQ Factor Xa Inhibitor): Acute DVT/PE, Hip/Knee/Abdominal Surgery prophylaxis. Argatraban (IV Direct Thrombin Inhibitor): HIT, Coronary Thrombosis in patients with HIT or high risk of HIT.
45 USE OF NEWER AGENTS: FDA APPROVAL Bivalirudin (IV Direct Thrombin Inhibitor): HIT, ACS for PCI Aspirin: What s old is new again (again!)
46 Rivaroxaban (Xarelto) Mechanism: Oral Direct Factor Xa inhibitor. Administration: Fixed dose. No lab monitoring required. Half-life: 5-9 hrs. Peak plasma concentration in 2.5 to 4hrs. Monitoring not needed.
47 Rivaroxaban FDA Approval Prophylaxis in elective Hip and Knee surgery (10 mg PO daily). Treatment of acute DVT and acute Pulmonary Embolism (15 mg PO BID). Prevention of recurrence after episode of acute DVT and acute PE (15 mg PO BID). Equal efficacy as Warfarin and possibly less bleeding risk (BMJ metanalysis 2012). Stroke prevention in non-valvular Atrial Fibrillation. Not recommended in patients with CrCl under 30 ml/min, significant hepatic dysfunction, or pregnant.
48 EINSTEIN-PE Investigators (NEJM 2012:366:1287) 4832 patients with symptomatic PE randomly assigned to rivaroxaban (15 mg BID for 3 wks and then 20 mg daily) vs enoxaparin (1 mg/kgm BID and then warfarin). Results: Risk of recurrent VTE the same (2.1 vs 1.8%), but risk of major bleeding less (1.1 vs 2.2%, but absolute benefit only 1.1%). Limitations: open-label study could increase the risk for bias.
49 Rivaroxaban Half life with normal renal function is only 5-9 hours. In non life-threatening bleeds discontinuation may be sufficient. No specific antidote exists. Activated Charcoal may remove unabsorbed drug from the GI tract. Dialysis not effective, but charcoal hemofiltration has been suggested. Life-threatening bleeding: Activated prothrombin complex concentrates (bebulin) has been suggested. Potential for use in patients with HIT.
50 Rivaroxaban for Prophylaxis in Medical Patients (NEJM Feb 2013) Placebo controlled trial with 8101 patients randomized to Rivaroxaban 10 mg PO daily vs Enoxaparin 40 mg SQ daily. Rivaroxaban was non-inferior in prevention of VTE, but there was an increased risk of bleeding.
51 APIXABAN Oral Factor Xa inhibitor. Half-life 8-15 hours. FDA approved for non-valvular A Fib. Approved in Europe for prophylaxis after hip or knee surgery. No antidote available.
52 Apixaban for Extended Treatment of Venous Thromboembolism (NEJM Feb 2013) 2486 patients in this randomized double-blind study of patients with VTE treated for 6-12 months with AC were randomized to placebo vs apixaban 2.5 mg BID (prophylactic dose) vs apixaban 5 mg BID (treatment dose) for an additional 12 months. Rate of VTE recurrence or VTE related death 8.8% vs 1.7% vs 1.7%. No difference in major or non-major bleeding. Not yet FDA approved for this indication.
53 Oral Abixaban for the Treatment of Acute Venous Thromboembolism (NEJM Aug 2013) 5395 patients with acute VTE double blind RCT Abixaban for 6 months vs enoxaparin/warfarin for 6 months. Abixaban was noninferior to enoxaparin/warfarin in the primary safety outcome of recurrent symptomatic VTE or death from VTE. Abixaban significantly less major bleeding and clinically relevant non-major bleeding. Not yet FDA approved.
54 Edoxaban vs Warfarin for extended treatment of Symptomatic VTE (NEJM October 2013) Edoxaban is an oral factor Xa inhibitor (similar to rivaroxaban). Not yet FDA approved. Randomized, double-blind, noninferiority trial of patient with VTE who received heparin initially and were then randomized to edoxaban 6o mg daily (30 mg daily for CrCl or weight under 60 kgm) vs warfarin for 3-12 months. Warfarin therapeutic range 63.5% of the time (40-50% in most reports. Conclusion: Edoxaban noninferior to warfarin and caused significantly less bleeding (8.5 vs 10.3%).
56 Dabigatran (Pradaxa) Orally active direct thrombin inhibitor. Only Approved by the FDA for prophylaxis in non-valvular atrial fibrillation with CrCl over 30 ml/min. Half-life hrs. Maximum AC effect in 2-3 hours. Drug interactions: rifampin, quinidine, ketoconazole, verapamil, amio, clari.
57 Dabigatran Studies Dabigratan 220 mg daily non-inferior to Enoxaparin 40 mg daily for prophylaxis after TKA or THA (Throm Haemost 2009;101:77). RE-COVER (NEJM 2009;361:2342): Randomized, Double blind, noninferiority trial of 2539 pts with acute VTE showed Dabigatran=Warfarin for 6 months in recurrent VTE, and in associated death and all bleeding and major bleeding. However, the substantial majority of these patients had DVT s, not PE s. Cost approx $8/day.
58 Dabigatran Drug Reversal Half-life only hrs. Hemodialysis: up to 60% removed in 2-3 hrs. Activated Charcoal removes unabsorbed drug in GI tract within 2 hrs of ingestion. Recombinant Factor VII A supported by limited data to reverse AC effect. Monoclonal AB capable of rapidly and completely inhibiting AC actively in a mouse model is being studied.
59 EXTENDED USE OF DABIGATRAN IN VTE (NEJM Feb 2013, TWO STUDIES) Patients completed at least 3 months of warfarin were randomized to dabigatran vs warfarin in one study, and dabigatran vs placebo in the other. Total duration of dabigatran 6-36 months Dabigatran non-inferior to warfarin in recurrent VTE (1.8% vs 1.3%) and lower risk of major bleeding (0.9% vs 1.8%). However, increased risk of ACS (0.9% vs 0.2%). Dabigatran vs placebo study: Less recurrent VTE (0.4% vs 5.6%), increased risk of bleeding (5.3% vs 1.8%). ACS the same.
60 Dabigratan: Risks Bleeding: US FDA and European Medicines Agency are investigating over 250 post-marketing reports of deaths due to bleeding. Median patient age is 80. MI or ACS: Metanalysis (Arch Intern Med 2012;172:397) of 7 randomized trials comparing dabigatran vs warfarin, enoxaparin, or placebo showed increased risk of MI or ACS (OR 1.19 vs. 0.79). Risk similar in the largest of these trials (RE-LY) showed an OR of Mechanical Heart Valves compared to warfarin: NEJM 9/1/13. Trial terminated prematurely due to excess of thromboembolic and bleeding events in the dabigatran group.
61 Fondaparinux (Arixtra) Synthetic pentasaccharide given SQ with inhibitory activity against Factor Xa. 100% bioavailable, peak level 1.7 hrs. Half-life 17 hrs. Can Monitor anit-factor Xa levels. FDA approved for: postop Hip surgery/knee surgery/abdominal surgery prophylaxis. FDA approved for DVT with similar efficacy and S/E s at 3 months as Enoxaparin. FDA approved for acute PE with efficacy and safety similar to IV Heparin.
62 Fondaparinux Doses: prophylaxis 2.5 mg SQ daily. treatment 5-10 mg SQ daily weight based. Clearance: Renal. Cautions: Under 50 kgm weight, CrCl < 30, plts < 100 Preop: stop 2-4 days in advance. Longer with renal dysfunction. HIT: reports of effectiveness off-label. Bleed: no antidote. High dose recombinant Factor VIIa (Novo-7) partially normalizes the PTT>
63 Argatroban Intravenous Direct Thrombin Inhibitor. Immediate onset of action. Steady state AC effect achieved in 1-3 hours. Very short halflife, effect wears off rapidly after discontinuation. FDA approved for HIT and for coronary thrombosis in patient with, or at risk for, HIT. Hepatic elimination, so avoid in the presence of liver failure.
64 Bivalirudin Intravenous Direct Thrombin Inhibitor. Approved by the FDA for use in patients with ACS undergoing PCI, and for HIT. Predominantly non-organ elimination by proteolysis and thus can be use in liver or renal dysfunction. Half-life of only 25 minutes.
65 Low-dose Aspirin after completion of treatment for VTE (ASPIRE STUDY, NEJM May ) Study of 800 patients with first episodes of unprovoked VTE. Aspirin given after completing course of warfarin. Primary Study Endpoint: Aspirin 100 mg daily was no better than placebo at preventing recurrent VTE up to a median f/u of 3 years (4.8% vs 6.5%). Secondary Endpoint: composite risk of a major vascular events (VTE recurrence, MI, Stroke, major bleeding, and death) were reduced by about 1/3.
66 WARFASA STUDY: NEJM May 2012 First time unprovoked DVT who had finished 6-18 months of AC, who were randomized to ASA 100 mg vs placebo. 6.6% recurrence rate in ASA group compared to 11.2 % in placebo group. No increase rate of major bleeding Summary of the two studies: Indefinite warfarin in this population substantially lowers the risk of recurrent VTE, but increases bleeding risk. ASA may be another alternative in this group of patients.
67 QUESTIONS OR COMMENTS?
68 ACCP Guidelines for Hospital Thromboprophylaxis of Medical Patients What drugs are recommended? When should SCD s be used?
69 Hospital Thromboprophylaxis LMWH, LDUH (BID or TID), or fondaparinux (1B). In ICU patients use LMWH or LDUH (2C). Use SCD s or graduated compression stockings if high risk of bleeding instead of the above (2C).
70 VENOUS THROMBOLISM PROPHYLAXIS IN HOSPITALIZED PATIENTS: A CLINICAL PRACTICE GUIDELINE FROM THE AMERICAN COLLEGE OF PHYSICIANS Ann Intern Med. 1 November 2011:155(9): Note: guidelines refer to hospitalized medical (not surgical) patients
71 Heparin vs no Heparin in nonstroke medical patients Randomized trials of Heparin vs no Heparin prophylaxis in non stroke medical patients did not show a significant reduction in mortality or in symptomatic DVT. There was an increased risk of all bleeding events (9 more events per 1000 persons treated). Non-significant increase in major bleeding (1 per 1000). There was a significant reduction in PE s (4 fewer PE s per 1000 persons treated). In most patients this was felt to outweigh the increased bleeding risk. Overall, the ACP recommends Heparin prophylaxis be used in medical patients unless a substantial contraindication exists.
72 Heparin vs no Heparin in acute Stroke Patients Heparin increased the risk of major bleeding (6 per 1000). This was felt to outweigh a non-significant reduction in PE s (3 per 1000). Heparin had no significant effect on mortality, symptomatic DVT, or PE. However, the pooled results showed wide CI s that also encompassed potential substantial net benefits.
73 The International Stroke Trial (Lancet. 1997:349: ) No significant difference between SQ Heparin vs no Heparin in 14 day mortality or in PE s. Increase in major bleeding (increase 5 in 1000) was offset by a larger decrease in risk for recurrent ischemic stroke (decrease 14 in 1000). Overall, while evidence for benefit in stroke patients is relatively weaker than for that in non-stroke medical patients, the ACP does recommend prophylaxis in stroke patients who are not at high risk of bleeding.
74 SQ UFH (2-3 times daily) vs SQ LMWH (once daily) No significant difference in clinical outcome. No significant difference in major bleeding. There was a Non-significant trend favoring LMWH over UFH for preventing PE. HIT: 7/1900 UFH vs 1/1900 LMWH (p=0.07). Wholesale drug cost: UFH $10/day, generic enoxaparin ($35/day), fondaparinux ($60/day). Fondaparinux has not been compared directly to heparin products for prophylaxis.
75 Graduated Compression Stockings in Patients with Acute Stroke No improvement in Clinical Outcome. Increased risk for lower extremity skin damage. Overall, the ACP recommends against the use of graduated compression stockings.
76 Intermittant Pneumatic Compression Shown beneficial in surgical patients. Thus, the ACP feels it may be a reasonable option in medical patients at high risk for bleeding or patients in whom heparin is contraindicated for other reasons.
77 Treatment of Chronic Thromboembolic Pulmonary Hypertension What medication is recommended? When is pulmonary thromboendarterectomy recommended?
78 Treatment of CTPH Lifetime treatment with Warfarin (1B). Thromboendarterectomy is recommended in patients with CTPH with central disease with experienced surgical expertise available (2C).
79 Treatment of SVT Are there any recommendations or suggestions for treatment?
80 Treatment of LE SVT Treatment is suggested if SVT is at least 5 cm in length with prophylactic dose of LMWH or fondaparinux for 45 days (2B).
81 Acute Isolated LE Distal DVT If no severe symptoms or risk factors for extension suggest serial US for 2 weeks and treat if extend to be proximal DVT. If severe symptoms or risk factors for extension the give AC for 3 months (not longer).
82 Splanchnic Vein Thrombosis Portal vein, mesenteric vein, or splenic vein with symptoms give AC (1B). Hepatic vein with symptoms give AC (2C). Incidentally detected portal, mesenteric, splenic or hepatic no AC (2C).
83 Prophylaxis in Outpatients with Malignancy Recommend against routine use of prophylactic LMWH or LDUH (2B) or warfarin (1B) unless the patient has another risk factor (such as prior VTE, immobilization, hormonal therapy, etc). With indwelling catheter recommend against prophylaxis with LMWH or LDUH (2B) or warfarin (2C) unless there is another risk factor.
84 Prophylaxis in chronically immmobilized patients Residing at home or nursing home is not recommended (2C).
85 D-Dimer Testing is Recommended in which of the Following Circumstances? 1. Patient with a moderate pre-test probability of DVT. 2. Patient with a high pre-test probability of DVT. 3. Patient being worked up for a PE. 4. None of the above. 5. All of the above.
86 Answer: Patient with a moderate pre-test prob for DVT Low or moderate prob of DVT: check D- dimer. If negative no further w/u is needed (1B). If positive get an US. High prob of DVT: check US. If US positive treat. High prob of DVT: If US negative check D-dimer. If D-dimer positive repeat US in one week.
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
UC SF Pulmonary Embolism Treatment Update Jeffrey Tabas, MD Professor UCSF School of Medicine Emergency Department San Francisco General Hospital sf g h Disclosure No Financial Relationships to Disclose
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.email@example.com This presentation will discuss unlabeled and investigational use of products The author
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
DEEP VEIN THROMBOSIS: TREATMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
Conserva)ve Treatment of PE/ DVT Amir Kaki, MD FACC FSCAI Asst Prof of Medicine Wayne St SOM Medical Director Cardiac Catheteriza)on Lab Heart Hospital DMC Detroit, MI Incidence Acute pulmonary embolism
Venous Thromboembolic Treatment Guidelines About the NYU Venous Thromboembolic Center (VTEC) The center s mission is to deliver advanced screening, detection, care, and management services for patients
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
Innovations in Treating VTE, Using the EDOU Disclosures No financial conflicts or disclosures Kelly Sawyer, MD, MS firstname.lastname@example.org Observation Symposium 2013 Objectives Overview of VTE Treatment
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
Advanced Issues in Peri-Operative VTE Prevention Michael-Anthony (M-A) Williams, M.D. Consultant Physician Centura Medical Consultants September 27th, 2012 Main Topics 1. The perils of the early mover-
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
New Oral Anticoagulants July 2012 Objectives Review coagulation cascade and previous treatment options for anticoagulation Understand points of interaction within coagulation cascade and new oral agents
+ New oral anticoagulants: A review of current indications November 2 nd, 2012 Dr. Sudeep Shivakumar, Hematology Dalhousie University + Objectives es To review indications for anticoagulation To discuss
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
Anticoagulation at the end of life Rhona Maclean Rhona.email@example.com Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA firstname.lastname@example.org Dabigatran and Rivaroxaban:
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
ANTICOAGULATION USE FOR THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASE Jamie N. Nadler, M.D. Assistant Professor of Medicine State University of New York at Buffalo Department of medicine Division
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS email@example.com Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
Anticoagulants for venous thromboembolic disease- Optimizing the old, ushering in the new. Daniel A. Forman, DO RPS Hematology Oncology firstname.lastname@example.org 610 509 5067 cell RHS Anticoagulation
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
New Anticoagulation Agents Use of New and Older Therapeutic Agents in the Treatment Regimen Michelle Geddes Case 1 40 year old woman with idiopathic proximal DVT. Previous heparin allergy (wheals, hives)
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013 General Principles: There is compelling data in the medical literature to support
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug
Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
Volume 4. AAOS Clinical Guideline on Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty Comparison with Other Guidelines Disclaimer This clinical guideline
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
Comparative Anticoagulation Laurajo Ryan, PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Austin College of Pharmacy The University of Texas Health Science Center Pharmacotherapy
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014 Thromboembolism epidemiology 5 million DVT s 900,000 PE s 290,000 fatalities Heit J. Blood. 2005;106:910. 10 VTE events Since this talk began DVT
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1 Roadmap for today
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
Eliquis (apixaban) Policy Number: 5.01.573 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Eliquis when it is determined to be medically necessary
CHEST Supplement ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
Xarelto (Rivaroxaban): Effective in a broad spectrum Joep Hufman, MD Medical Scientific Liason Xarelto : Effective in a broad spectrum Introduction Therapeutic areas SPAF VTE Prevention VTE treatment Practical
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) New Indication: Pulmonary Embolism Note: The Canadian Drug Expert Committee (CDEC) previously reviewed rivaroxaban for the treatment of deep vein
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) The contents of this CPG are to be used as a guide. Healthcare professionals
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
Direct Oral Anticoagulants (DOACs) Who Gets What? Kathryn Hassell, MD Professor of Medicine, Division of Hematology University of Colorado Denver Disclosures No financial or commercial conflicts of interest
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
CHEST Supplement ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF Recorded Webcast Update for Analysts and Investors March 26, 2012 1 Webcast Presentation Agenda EINSTEIN PE Clinical Trial